Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPASHOCK
2023-503602-37-00Phase 3Authorised
- Sponsor
- CHRU Nancy
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cardiogenic shock comparing Empagliflozin plus standard of care with Standard of care alone (2 arms). Primary endpoint: Hierarchical composite endpoint (win-ratio). Planned start Apr 2024; status: authorised.
02
Drugs
empagliflozin
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2023-503602-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503602-37-00.